<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pathogens</journal-id><journal-id journal-id-type="iso-abbrev">Pathogens</journal-id><journal-id journal-id-type="publisher-id">pathogens</journal-id><journal-title-group><journal-title>Pathogens</journal-title></journal-title-group><issn pub-type="epub">2076-0817</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7692590</article-id><article-id pub-id-type="pmid">33120980</article-id><article-id pub-id-type="doi">10.3390/pathogens9110889</article-id><article-id pub-id-type="publisher-id">pathogens-09-00889</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Chemical Composition and In Vitro Antiplasmodial Activity of the Ethanolic Extract of <italic>Cyperus articulatus</italic> var. <italic>nodosus</italic> Residue</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4208-6271</contrib-id><name><surname>de Assis</surname><given-names>Francisco Fl&#x000e1;vio Vieira</given-names></name><xref ref-type="aff" rid="af1-pathogens-09-00889">1</xref></contrib><contrib contrib-type="author"><name><surname>da Silva</surname><given-names>Nazar&#x000e9; Carneiro</given-names></name><xref ref-type="aff" rid="af2-pathogens-09-00889">2</xref></contrib><contrib contrib-type="author"><name><surname>Moraes</surname><given-names>Waldiney Pires</given-names></name><xref ref-type="aff" rid="af2-pathogens-09-00889">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0909-769X</contrib-id><name><surname>Barata</surname><given-names>Lauro Euclides Soares</given-names></name><xref ref-type="aff" rid="af3-pathogens-09-00889">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6742-3652</contrib-id><name><surname>Minervino</surname><given-names>Antonio Humberto Hamad</given-names></name><xref ref-type="aff" rid="af1-pathogens-09-00889">1</xref><xref rid="c1-pathogens-09-00889" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pathogens-09-00889"><label>1</label>Laboratory of Animal Health, LARSANA, Federal University of Western Par&#x000e1;, UFOPA, Santar&#x000e9;m, Par&#x000e1; 68040-255, Brazil; <email>flavioassis131995@hotmail.com</email></aff><aff id="af2-pathogens-09-00889"><label>2</label>Pharmacology Laboratory, Federal University of Western Par&#x000e1;, Santar&#x000e9;m, Par&#x000e1; 68040-255, Brazil; <email>nazaresilvaufopa@hotmail.com</email> (N.C.d.S.); <email>waldineypires@gmail.com</email> (W.P.M.)</aff><aff id="af3-pathogens-09-00889"><label>3</label>Laboratory for Research &#x00026; Development of Bioactive Products, Federal University of Western Par&#x000e1;, Santar&#x000e9;m, Par&#x000e1; 68040-255, Brazil; <email>lauroesbarata@gmail.com</email></aff><author-notes><corresp id="c1-pathogens-09-00889"><label>*</label>Correspondence: <email>ah.minervino@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2020</year></pub-date><volume>9</volume><issue>11</issue><elocation-id>889</elocation-id><history><date date-type="received"><day>10</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><italic>Cyperus articulatus</italic> L. is popularly known as priprioca. Its rhizomes are used as a medicine in the treatment of malaria in traditional medicine. Since priprioca oil is extracted for commercial purpose, we evaluated if the components from the priprioca residue can be a source of antiplasmodial active molecules. This study aimed to determine the in vitro antiplasmodial and cytotoxicity activities of the ethanolic extract of <italic>C. articulatus</italic> as an in vitro antiplasmodial agent. From the solid residue of the plant rhizomes, 40 g samples were removed and subjected to hot extraction using a Soxhlet extractor. The in vitro antiplasmodial activity was determined using the W2 and 3D7 strains of <italic>P. falciparum</italic>. The phytochemical study identified the following main compounds: corymbolone (14.25%), cyclocolorenone (9.75%), and cadalene (8.36%). The extract exhibited moderate IC<sub>50</sub> (inhibitory concentration) against the two strains of <italic>P. falciparum</italic>: 1.21 &#x000b1; 0.01 against the W2 strain and 1.10 &#x000b1; 0.06 &#x000b5;g/mL against the 3D7 strain. Our results show the therapeutic potential of priprioca residue as a low-cost antiplasmodial agent.</p></abstract><kwd-group><kwd>malaria</kwd><kwd>priprioca</kwd><kwd>phytotherapic</kwd><kwd>antimalarial</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-pathogens-09-00889"><title>1. Introduction</title><p>Malaria is an infectious, parasitic disease that affects millions of people in the tropical and subtropical regions worldwide, mainly in Africa, Southeast Asia, and the Amazon region of South America [<xref rid="B1-pathogens-09-00889" ref-type="bibr">1</xref>,<xref rid="B2-pathogens-09-00889" ref-type="bibr">2</xref>,<xref rid="B3-pathogens-09-00889" ref-type="bibr">3</xref>]. According to the World Health Organization [<xref rid="B4-pathogens-09-00889" ref-type="bibr">4</xref>], there were 228 million cases of malaria worldwide in 2018 with 405,000 deaths. Malaria is considered the most important potentially fatal parasitic disease of human beings [<xref rid="B5-pathogens-09-00889" ref-type="bibr">5</xref>].</p><p>In Brazil, most cases are in the Amazon region, owing to, among other factors, the favorable conditions for the existence of the vector, the lack of adequate sanitation, potential risk of zoonotic transmission from nonhuman primates, and disorderly settlements near too forested areas, causing serious problems in public health and great economic impact affecting millions of people [<xref rid="B6-pathogens-09-00889" ref-type="bibr">6</xref>,<xref rid="B7-pathogens-09-00889" ref-type="bibr">7</xref>,<xref rid="B8-pathogens-09-00889" ref-type="bibr">8</xref>].</p><p>Malaria, a disease caused by protozoa belonging to <italic>Plasmodium</italic>, has a large impact on the world, putting at risk approximately 40% of the world population (about 2.4 billion people) in more than 100 countries [<xref rid="B9-pathogens-09-00889" ref-type="bibr">9</xref>]. This disease is transmitted to humans by infected female <italic>Anopheles</italic> mosquitoes. <italic>P. falciparum</italic> is the most dangerous species of the genus because it can lead to the most severe form of malaria, cerebral malaria, which without treatment is invariably fatal and in patients treated adequately the mortality rate is around 15&#x02013;20% [<xref rid="B10-pathogens-09-00889" ref-type="bibr">10</xref>,<xref rid="B11-pathogens-09-00889" ref-type="bibr">11</xref>].</p><p>The resistance of <italic>P. falciparum</italic> to artemisinin derivatives in Southeast Asia threatens malaria control [<xref rid="B12-pathogens-09-00889" ref-type="bibr">12</xref>,<xref rid="B13-pathogens-09-00889" ref-type="bibr">13</xref>]. High prevalence of <italic>P. vivax</italic> genotypes associated with chloroquine resistance highlights the severe situation of Malaria treatment in Oceania and South Asian regions [<xref rid="B14-pathogens-09-00889" ref-type="bibr">14</xref>]. The search for new drugs for treatment is steadily increasing because of the parasite&#x02019;s resistance to traditional therapy [<xref rid="B15-pathogens-09-00889" ref-type="bibr">15</xref>].</p><p>The importance of natural products, including those derived from plants, is recognized in the development of therapeutic drugs for different purposes in animals [<xref rid="B16-pathogens-09-00889" ref-type="bibr">16</xref>] and humans. Approximately 40% of the drugs currently available have been developed directly or indirectly from natural sources, of which 25% are from plants [<xref rid="B17-pathogens-09-00889" ref-type="bibr">17</xref>,<xref rid="B18-pathogens-09-00889" ref-type="bibr">18</xref>]. There is a great diversity of plant species worldwide and in the Brazilian Amazon, with the potential for investigation of new secondary metabolites with antiplasmodial action [<xref rid="B6-pathogens-09-00889" ref-type="bibr">6</xref>,<xref rid="B19-pathogens-09-00889" ref-type="bibr">19</xref>]. <italic>Cyperus articulatus</italic> L. belongs to the <italic>Cyperaceae</italic> family and is popularly known as priprioca in Brazil, mainly in the Amazon region, where it is traditionally used as a sedative, anticonvulsant, and anti-inflammatory agent [<xref rid="B20-pathogens-09-00889" ref-type="bibr">20</xref>]. Its rhizomes are used as a source of herbal medicines for fever and seizures and in the treatment of malaria in traditional medicine [<xref rid="B21-pathogens-09-00889" ref-type="bibr">21</xref>]. There has been a growing interest in studies of <italic>C. articulatus</italic> in recent years owing to the pleasant aroma of the volatile oil obtained from the rhizome of the plant for perfumery industry [<xref rid="B20-pathogens-09-00889" ref-type="bibr">20</xref>] and its medicinal effects.</p><p>When essential oil is removed from priprioca rhizome, organic solid waste is generated which still contains significant amounts of metabolites with medicinal activity. In this context, the objective of the present study was to assess the effect of the ethanolic extract of <italic>C. articulatus</italic> rhizome residue as an in vitro antiplasmodial agent.</p></sec><sec id="sec2-pathogens-09-00889"><title>2. Material and Methods</title><sec id="sec2dot1-pathogens-09-00889"><title>2.1. Collection and Identification of Plant Materials</title><p>Rhizomes of the species <italic>Cyperus articulatus</italic> var. <italic>nodosus,</italic> popularly known as priprioca, were collected in August 2014, in the Tabocal region of the municipality of Santar&#x000e9;m, Par&#x000e1;, Brazil (&#x02212;54&#x000b0;43&#x02019;00.10&#x0201d; W &#x02212;02&#x000b0;37&#x02019;41.10&#x0201d; S). The species was identified by the botanist Dr. Ant&#x000f4;nio Elielson Sousa da Rocha, from the Museu Paraense Emilio Goeldi, where a specimen is deposited (MG-207174). The plant&#x02019;s name was verified on the online website (<uri xlink:href="www.theplantlist.org">www.theplantlist.org</uri>) of the Royal Botanic Gardens, Kew, accessed on July 7, 2020.</p></sec><sec id="sec2dot2-pathogens-09-00889"><title>2.2. Preparation of the Ethanolic Extract of C. articulatus (EECA)</title><p>Five kilograms of the rhizomes of <italic>C. articulatus</italic> were collected. After collection, the rhizomes were cleaned, dried for three consecutive days, and ground in a knife mill in an open environment. After drying, the crushed material was subjected to hydrodistillation by a 150 L steam distillation system for 1.5 to 4 h, to obtain the essential oil. From the solid vegetable residue waste originating from the extraction by steam system, 40 g samples were removed and subjected to hot extraction in a Soxhlet extractor using ethanol 96%. The solvent of the solution resulting from the hot extraction was evaporated in a rotary evaporator under reduced pressure to obtain a concentrate of the ethanolic extract of the residue of <italic>C. articulatus</italic>.</p></sec><sec id="sec2dot3-pathogens-09-00889"><title>2.3. Chromatographic Analysis of the EECA</title><p>The analysis of the chemical composition of the EECA was performed in an Agilent gas chromatograph, model HP-6890 equipped with a selective Agilent mass detector, model HP-5975 using an HP-5MS capillary column (30 m &#x000d7; 0.25 mm &#x000d7; 0.25 &#x000b5;m) under the following conditions: injector temperature = 250 &#x000b0;C, column = 80 &#x000b0;C, heating rate = 5 &#x000b0;C/min to 280 &#x000b0;C (20 min), and detector = 300 &#x000b0;C. Helium was used as carrier gas at a flow rate of 1 mL/min and a selective mass detector operating at 70 eV, m/z = 30 to 500 u.m.a. The EECA was solubilized in ethyl acetate at a concentration of 20 mg/mL and the identification of the major compounds in the extract was performed by comparison with the electronic library of the equipment (NIST-11).</p></sec><sec id="sec2dot4-pathogens-09-00889"><title>2.4. Assessment of Cell Viability</title><p>For the analysis of cell viability, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, Inc. St. Louis, MO, USA) was used with the cell line WI-26VA-4 (lung fibroblast ATCC CCL-95.1); this strain is part of the animal cell bank of the Cell Biology Service (SBC) of the Ezequiel Dias Foundation (FUNED). The cells were maintained in RPMI1640 medium supplemented with 21 mM bicarbonate, 40 mg/mL gentamicin, and 10% (<italic>v</italic>/<italic>v</italic>) inactivated fetal bovine serum. A cell suspension was distributed in a 96-well plate at a concentration of 1 &#x000d7; 10<sup>5</sup> cells/well, and incubated for 24 h at 37 &#x000b0;C in a humid atmosphere containing 5% CO<sub>2</sub>. After that, the cells were washed with phosphate-buffered saline. Subsequently, the EECA was added at different concentrations, ranging from 1000 to 0.1 &#x003bc;g/mL. After 48 h of incubation, the plate was washed again with phosphate-buffered saline with 100 &#x003bc;L of MTT tetrazolium salt added at a concentration of 5 mg/mL. The plate was incubated again for another 3 h. After discarding the supernatant, 50 &#x003bc;L of dimethyl sulfoxide (DMSO, Sigma-Aldrich, Inc. St. Louis, MO, USA)) was added, and the color obtained was evaluated by reading on a microplate spectrophotometer (model Espectramax M5e, Molecular Devices LLC, San Jose, CA, USA) at a wavelength of 550 nm. The concentration that inhibited cell growth by 50% (LC<sub>50</sub>) was determined in comparison to cells cultured without the test compound.</p></sec><sec id="sec2dot5-pathogens-09-00889"><title>2.5. Evaluation of Hemolytic Activity</title><p>Fresh blood (5 mL) was collected in an EDTA tube and centrifuged at 1000&#x000d7; <italic>g</italic> for 5 min at 4 &#x000b0;C. The supernatant was removed, and the pellet with red blood cells was washed five times with saline solution (0.9% sterile) and then suspended in the same solution to obtain a 1% (<italic>v/v</italic>) red cell solution. The test compound was diluted in a 1% DMSO solution and tested in triplicate at concentrations of 1000 to 15.6 &#x003bc;g/mL in seven serial dilutions (1:2), and 100 &#x003bc;L of the 1% red blood cell suspension was added (<italic>v/v</italic>) in each well. The resulting suspensions were incubated for 60 min at 37 &#x000b0;C. After incubation, the samples were centrifuged for 2 min at 1000&#x000d7; <italic>g</italic>. The supernatants were transferred to 96-well plates and the release of hemoglobin was measured by absorbance at 450 nm (Abs450nm) using a BioTek Synergy HT multiplate reader. To control 100% hemolysis, red blood cells were suspended in 1% (<italic>v/v</italic>) Triton X-100. As a control without hemolysis, a 0.9% saline solution was used. The percentage of hemolysis was determined using the following equation: [(Abs450nm treated sample-Abs450nm untreated)/(Abs450nm1% Triton X-100-Abs450nm untreated)] &#x000d7; 100 [<xref rid="B22-pathogens-09-00889" ref-type="bibr">22</xref>].</p></sec><sec id="sec2dot6-pathogens-09-00889"><title>2.6. Evaluation of In Vitro Antiplasmodial Activity</title><p>In vitro antiplasmodial activity was determined using W2 (chloroquine-resistant) and 3D7 (chloroquine-sensitive) strains of <italic>Plasmodium falciparum</italic> grown in human A+ red blood cells in a predominantly ring stage, synchronized using the sorbitol method [<xref rid="B23-pathogens-09-00889" ref-type="bibr">23</xref>]. RPMI 1640 culture medium supplemented with 25 mM HEPES, 21 mM sodium bicarbonate, 300 mM hypoxanthine, 11 mM glucose, 40 mg/mL gentamicin, and 10% (<italic>v</italic>/<italic>v</italic>) inactivated human plasma was used. The cultures synchronized with 2% parasitemia and 2% hematocrit were distributed in a 96-well microplate. The EECA was added at a starting concentration of 50 &#x003bc;g/mL and twofold serial diluted in incomplete culture medium and 4% DMSO until the final concentration of 0.049 &#x003bc;g/mL. We tested the following concentrations of ECA: 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.39, 0.195, 0.098, 0.049 &#x003bc;g/mL. Chloroquine was used as a standard antimalarial. The plate was incubated for 48 h at 37 &#x000b0;C with 5% CO<sub>2</sub> and 95% relative humidity. Smears corresponding to each well were made. After being fixed with methanol and stained with Giemsa, the smears were used to count the parasitemia under an optical microscope (1000&#x000d7;). The activity of the compounds was expressed as the percentage of reduction in parasitemia in relation to the negative control (without any antiplasmodial drug), which was considered as 100% of the growth of the parasite. The experiment was performed in triplicate with each concentration of EECA extract, positive and negative controls, tested three times, totaling 39 independent assays per strain (total of 78). The slide reading was blinded (i.e., the slides had codes, and the observer did not know the treatment used in each slide) and performed by the same trained researcher. The concentration of extract that inhibited 50% of the growth of the parasite (IC<sub>50</sub>) was determined through dose&#x02013;response curves, as a function of nonlinear regression.</p></sec><sec id="sec2dot7-pathogens-09-00889"><title>2.7. Selectivity Index</title><p>The selectivity index (SI) is the relationship between the cytotoxic and antiparasitic activities of each compound. The SI was obtained from the ratio between the LC<sub>50</sub> value for WI cell line and the IC<sub>50</sub> for <italic>P. falciparum</italic> (strain W2) according to the formula: SI = LC<sub>50</sub> cell line WI/IC<sub>50</sub>
<italic>P. falciparum</italic> (strain W2). Values greater than 10 were considered indicative of high selectivity, whereas substances with values below 10 were considered to have low selectivity [<xref rid="B24-pathogens-09-00889" ref-type="bibr">24</xref>].</p></sec><sec id="sec2dot8-pathogens-09-00889"><title>2.8. Statistical Analysis</title><p>Statistical analyses were performed using OriginPro 8.0 (OriginLab Corporation, Northampton, MA, USA) to determine the IC<sub>50</sub> value of the in vitro test.</p></sec></sec><sec sec-type="results" id="sec3-pathogens-09-00889"><title>3. Results</title><p>The phytochemical study of the ethanolic extract of <italic>C. articulatus</italic> obtained from residues derived from the extraction of essential oil resulted in the identification of the following main compounds: alpha-bulnesene, cadalene, cyperotundone, cis-thujopsenal, cyclocolorenone, corymbolone, hexadecanoic acid ethyl ester, 9,12-octadecanoic acid ethyl ester, 9-octadecenoic acid ethyl ester, and cholesta-3,5-diene. Together, these compounds represented more than 60% of the total sample (<xref rid="pathogens-09-00889-t001" ref-type="table">Table 1</xref>).</p><p>The compound identification shows the presence of mainly sesquiterpenes, wherein the highest yield (14.25%) was obtained for corymbolone. The EECA at the tested concentrations did not show hemolysis, similar to the control with 0.9% saline.</p><p>In the in vitro antiplasmodial test, the EECA presented an IC<sub>50</sub> value of 1.21 &#x000b1; 0.01 obtained from dose&#x02013;response curves for the culture of <italic>P. falciparum</italic> against the W2 strain (chloroquine-resistant) and an IC<sub>50</sub> value of 1.10 &#x000b1; 0.06 against the 3D7 strain (chloroquine-sensitive) (<xref rid="pathogens-09-00889-t002" ref-type="table">Table 2</xref>). In the cytotoxicity test with the WI cell line, using the MTT colorimetric method, the EECA showed an LC<sub>50</sub> value of &#x0003e; 100. In calculating the SI based on the ratio between the toxic dose and its antimalarial activity, <italic>P. falciparum</italic> demonstrated that the EECA is a safe compound with SI values &#x0003e; 91 for the 3D7 strain and 83 for the strain W2 (<xref rid="pathogens-09-00889-t002" ref-type="table">Table 2</xref>).</p></sec><sec sec-type="discussion" id="sec4-pathogens-09-00889"><title>4. Discussion</title><p>Preliminary studies evaluating the extract of <italic>C. articulatus</italic> also identified elevated concentration of corymbolone among all the other identified substances and showed in vitro antiplasmodial activity [<xref rid="B25-pathogens-09-00889" ref-type="bibr">25</xref>]. Considering the verified antiplasmodial action and the low toxicity of this molecule, it may has potential to be used as an alternative of chloroquine, which has adverse effects [<xref rid="B26-pathogens-09-00889" ref-type="bibr">26</xref>,<xref rid="B27-pathogens-09-00889" ref-type="bibr">27</xref>]. Alpha-bulnesene has biological activity related to the inhibition of platelet activation factor [<xref rid="B28-pathogens-09-00889" ref-type="bibr">28</xref>]. Toxicity analysis, which is necessary when investigating the biological activity of products with potential for phytotherapy, is conducted with the objective of determining the potential of new substances and products without causing risk to human health and classifying them according to their potential for lethality or toxicity as established by legislation [<xref rid="B29-pathogens-09-00889" ref-type="bibr">29</xref>].</p><p>Research using ethanol extract from leaves of <italic>Montrichardia linifera</italic> (Arruda) Schott showed moderate antiplasmodial activity (10 &#x0003c; IC<sub>50</sub> &#x0003c; 100 &#x003bc;g/mL) [<xref rid="B30-pathogens-09-00889" ref-type="bibr">30</xref>], which is below that found in this study (IC<sub>50</sub> = 1.21 &#x000b5;g/mL). However, work with <italic>Artemisia turcomanica</italic> extract obtained antiplasmodial activity with IC<sub>50</sub> and IC90 values of 0.90 &#x000b1; 0.27 mg/mL and 1.62 &#x000b1; 0.68 mg/mL, respectively [<xref rid="B31-pathogens-09-00889" ref-type="bibr">31</xref>].</p><p>As for cytotoxic activity, one study found that <italic>C. articulatus</italic> essential oil was moderately cytotoxic to monkey kidney cells [<xref rid="B32-pathogens-09-00889" ref-type="bibr">32</xref>]. However, with <italic>C. articulatus</italic> essential oil, a noncytotoxic result was obtained for human pulmonary fibroblasts by cell viability assay with MTT (LC<sub>50</sub> &#x0003e; 100 &#x003bc;g/mL) [<xref rid="B32-pathogens-09-00889" ref-type="bibr">32</xref>]. It was also observed that the IC<sub>50</sub> of W2 and 3D7 strains of <italic>P. falciparum</italic> treated with essential oil were 1.21 &#x003bc;g/mL and 2.30 &#x003bc;g/mL, respectively [<xref rid="B33-pathogens-09-00889" ref-type="bibr">33</xref>], consistent with the findings in this study. </p><p>In addition, an in silico study of the activities of triterpenes and iridoids isolated from <italic>Himatanthus articulatus</italic> (Vahl) Woodson did not identify any molecules with antiplasmodial activity [<xref rid="B34-pathogens-09-00889" ref-type="bibr">34</xref>]. One limitation of the present study is related to the source of antiplasmodial activity. We found three major components in the residue extract, corymbolone (14.25%), cyclocolorenone (9.75%), and cadalene (8.36%). The antimalarial activity is most likely from one of those or from a combined effect between two or more compounds present in the tested extract. Further studies are required to verify the antiplasmodial activity using purified chemical components found in the ethanolic extract of priprioca residue, which could be used as a new drug for malaria treatment.</p></sec><sec id="sec5-pathogens-09-00889"><title>5. Conclusions</title><p>The ethanolic extract obtained from the rhizome residue of <italic>Cyperus articulatus</italic> from Santar&#x000e9;m, Brazil, contained corymbolone as the main compound identified and exhibited a moderate level of activity against two strains of <italic>Plasmodium falciparum</italic> (W2 and 3D7). The EECA also showed low cytotoxicity against the human cell line WI-26-VA-4. Our results demonstrate the therapeutic potential of <italic>C. articulatus</italic> as an antiplasmodial agent.</p></sec></body><back><ack><title>Acknowledgments</title><p>Antonio H. H. Minervino is a recipient of a research productivity fellowship from National Council for Scientific and Technological Development (CNPq), Brazil.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization: F.F.V.d.A., A.H.H.M., L.E.S.B., A.H.H.M.; Experiments: F.F.V.d.A., N.C.d.S., W.P.M.; Data analysis: W.P.M., L.E.S.B., A.H.H.M.; Chemical analysis: L.E.S.B.; Writing manuscript: F.F.V.d.A., N.C.d.S.; Revising manuscript: A.H.H.M., W.P.M., L.E.S.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research received no external funding. </p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pathogens-09-00889"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laveran</surname><given-names>A.</given-names></name></person-group><article-title>Un nouveau parasite trouv&#x000e9; dans le sang de malades atteints de fi&#x000e8;vre palustre. Origine parasitaire des accidents de l&#x02019;impaludisme</article-title><source>Bull. M&#x000e9;m. Soc. M&#x000e9;d. H&#x000f4;pitaux Paris</source><year>1881</year><volume>17</volume><fpage>158</fpage><lpage>164</lpage></element-citation></ref><ref id="B2-pathogens-09-00889"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashley</surname><given-names>E.A.</given-names></name><name><surname>Pyae Phyo</surname><given-names>A.</given-names></name><name><surname>Woodrow</surname><given-names>C.J.</given-names></name></person-group><article-title>Malaria</article-title><source>Lancet</source><year>2018</year><volume>391</volume><fpage>1608</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)30324-6</pub-id><pub-id pub-id-type="pmid">29631781</pub-id></element-citation></ref><ref id="B3-pathogens-09-00889"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Espinoza</surname><given-names>J.</given-names></name></person-group><article-title>Malaria Resurgence in the Americas: An Underestimated Threat</article-title><source>Pathogens</source><year>2019</year><volume>8</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens8010011</pub-id><?supplied-pmid 30669301?><pub-id pub-id-type="pmid">30669301</pub-id></element-citation></ref><ref id="B4-pathogens-09-00889"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>World Malaria Report 2019</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2019</year><isbn>978-92-4-156572-1</isbn></element-citation></ref><ref id="B5-pathogens-09-00889"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahmana</surname><given-names>H.</given-names></name><name><surname>Mediannikov</surname><given-names>O.</given-names></name></person-group><article-title>Mosquito-borne diseases emergence/resurgence and how to effectively control it biologically</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><elocation-id>310</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9040310</pub-id><?supplied-pmid 32340230?><pub-id pub-id-type="pmid">32340230</pub-id></element-citation></ref><ref id="B6-pathogens-09-00889"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meneguetti</surname><given-names>D.U.O.</given-names></name><name><surname>Cunha</surname><given-names>R.M.d.</given-names></name><name><surname>Lima</surname><given-names>R.A.</given-names></name><name><surname>Oliveira</surname><given-names>F.A.S.</given-names></name><name><surname>de Medeiros</surname><given-names>D.S.</given-names></name><name><surname>Passarini</surname><given-names>G.M.</given-names></name><name><surname>de Medeiros</surname><given-names>P.S.D.M.</given-names></name><name><surname>Milit&#x000e3;o</surname><given-names>J.S.L.T.</given-names></name><name><surname>Facundo</surname><given-names>V.A.</given-names></name></person-group><article-title>Antimalarial ethnopharmacology in the Brazilian Amazon</article-title><source>J. Basic Appl. Pharm. Sci.</source><year>2014</year><volume>35</volume><fpage>385</fpage><lpage>392</lpage></element-citation></ref><ref id="B7-pathogens-09-00889"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiners</surname><given-names>A.A.O.</given-names></name><name><surname>de Azevedo</surname><given-names>R.C.S.</given-names></name><name><surname>Ricci</surname><given-names>H.A.</given-names></name><name><surname>de Souza</surname><given-names>T.G.</given-names></name></person-group><article-title>User adherence and reactions to malaria treatment: Implications for health education</article-title><source>Texto Context. Enferm.</source><year>2010</year><volume>19</volume><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1590/S0104-07072010000300016</pub-id></element-citation></ref><ref id="B8-pathogens-09-00889"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monteiro</surname><given-names>E.F.</given-names></name><name><surname>Fernandez-Becerra</surname><given-names>C.</given-names></name><name><surname>da Araujo</surname><given-names>M.S.</given-names></name><name><surname>Messias</surname><given-names>M.R.</given-names></name><name><surname>Ozaki</surname><given-names>L.S.</given-names></name><name><surname>de Duarte</surname><given-names>A.M.R.C.</given-names></name><name><surname>Bueno</surname><given-names>M.G.</given-names></name><name><surname>Catao-Dias</surname><given-names>J.L.</given-names></name><name><surname>Chagas</surname><given-names>C.R.F.</given-names></name><name><surname>da Mathias</surname><given-names>B.S.</given-names></name><etal/></person-group><article-title>Naturally Acquired Humoral Immunity against Malaria Parasites in Non-Human Primates from the Brazilian Amazon, Cerrado and Atlantic Forest</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><elocation-id>525</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9070525</pub-id><?supplied-pmid 32610598?><pub-id pub-id-type="pmid">32610598</pub-id></element-citation></ref><ref id="B9-pathogens-09-00889"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>A.P.</given-names></name><name><surname>Vitorino</surname><given-names>R.R.</given-names></name><name><surname>de Costa</surname><given-names>A.P.</given-names></name><name><surname>de Mendon&#x000e7;a</surname><given-names>E.G.</given-names></name><name><surname>de Oliveira</surname><given-names>M.G.A.</given-names></name><name><surname>Siqueira-Batista</surname><given-names>R.</given-names></name></person-group><article-title>Severe <italic>Plasmodium falciparum</italic> malaria</article-title><source>Rev. Bras. Ter. Intensiva</source><year>2011</year><volume>23</volume><fpage>358</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1590/S0103-507X2011000300015</pub-id><?supplied-pmid 23949409?><pub-id pub-id-type="pmid">23949409</pub-id></element-citation></ref><ref id="B10-pathogens-09-00889"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fran&#x000e7;a</surname><given-names>T.C.C.</given-names></name><name><surname>Dos Santos</surname><given-names>M.G.</given-names></name><name><surname>Figueroa-Villar</surname><given-names>J.D.</given-names></name></person-group><article-title>Mal&#x000e1;ria: Aspectos hist&#x000f3;ricos e quimioterapia</article-title><source>Quim. Nova</source><year>2008</year><volume>31</volume><fpage>1271</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1590/S0100-40422008000500060</pub-id></element-citation></ref><ref id="B11-pathogens-09-00889"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Idro</surname><given-names>R.</given-names></name><name><surname>Marsh</surname><given-names>K.</given-names></name><name><surname>John</surname><given-names>C.C.</given-names></name><name><surname>Newton</surname><given-names>C.R.J.</given-names></name></person-group><article-title>Cerebral malaria: Mechanisms of brain injury and strategies for improved neurocognitive outcome</article-title><source>Pediatr. Res.</source><year>2010</year><volume>68</volume><fpage>267</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1203/PDR.0b013e3181eee738</pub-id><?supplied-pmid 20606600?><pub-id pub-id-type="pmid">20606600</pub-id></element-citation></ref><ref id="B12-pathogens-09-00889"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariey</surname><given-names>F.</given-names></name><name><surname>Witkowski</surname><given-names>B.</given-names></name><name><surname>Amaratunga</surname><given-names>C.</given-names></name><name><surname>Beghain</surname><given-names>J.</given-names></name><name><surname>Langlois</surname><given-names>A.C.</given-names></name><name><surname>Khim</surname><given-names>N.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Duru</surname><given-names>V.</given-names></name><name><surname>Bouchier</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A molecular marker of artemisinin-resistant <italic>Plasmodium falciparum</italic> malaria</article-title><source>Nature</source><year>2014</year><volume>505</volume><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/nature12876</pub-id><?supplied-pmid 24352242?><pub-id pub-id-type="pmid">24352242</pub-id></element-citation></ref><ref id="B13-pathogens-09-00889"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashley</surname><given-names>E.A.</given-names></name><name><surname>Dhorda</surname><given-names>M.</given-names></name><name><surname>Fairhurst</surname><given-names>R.M.</given-names></name><name><surname>Amaratunga</surname><given-names>C.</given-names></name><name><surname>Lim</surname><given-names>P.</given-names></name><name><surname>Suon</surname><given-names>S.</given-names></name><name><surname>Sreng</surname><given-names>S.</given-names></name><name><surname>Anderson</surname><given-names>J.M.</given-names></name><name><surname>Mao</surname><given-names>S.</given-names></name><name><surname>Sam</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Spread of artemisinin resistance in <italic>Plasmodium falciparum</italic> malaria</article-title><source>New Engl. J. Med.</source><year>2014</year><volume>371</volume><fpage>411</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1314981</pub-id><?supplied-pmid 25075834?><pub-id pub-id-type="pmid">25075834</pub-id></element-citation></ref><ref id="B14-pathogens-09-00889"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noisang</surname><given-names>C.</given-names></name><name><surname>Meyer</surname><given-names>W.</given-names></name><name><surname>Sawangjaroen</surname><given-names>N.</given-names></name><name><surname>Ellis</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>R.</given-names></name></person-group><article-title>Molecular Detection of Antimalarial Drug Resistance in <italic>Plasmodium vivax</italic> from Returned Travellers to NSW, Australia during 2008&#x02013;2018</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><elocation-id>101</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9020101</pub-id></element-citation></ref><ref id="B15-pathogens-09-00889"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>T.N.C.</given-names></name><name><surname>van Huijsduijnen</surname><given-names>R.H.</given-names></name><name><surname>van Voorhis</surname><given-names>W.C.</given-names></name></person-group><article-title>Malaria medicines: A glass half full?</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>424</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1038/nrd4573</pub-id><pub-id pub-id-type="pmid">26000721</pub-id></element-citation></ref><ref id="B16-pathogens-09-00889"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Am&#x000e9;rico</surname><given-names>&#x000c1;.V.L.d.S.</given-names></name><name><surname>Nunes</surname><given-names>K.M.</given-names></name><name><surname>Assis</surname><given-names>F.F.V.</given-names></name><name><surname>Dias</surname><given-names>S.R.</given-names></name><name><surname>Passos</surname><given-names>C.T.S.</given-names></name><name><surname>Morini</surname><given-names>A.C.</given-names></name><name><surname>Ara&#x000fa;jo</surname><given-names>J.A.</given-names></name><name><surname>Castro</surname><given-names>K.C.F.</given-names></name><name><surname>Escher</surname><given-names>S.K.S.</given-names></name><name><surname>Barata</surname><given-names>L.E.S.</given-names></name><etal/></person-group><article-title>Efficacy of Phytopharmaceuticals from the Amazonian Plant Libidibia ferrea for Wound Healing in Dogs</article-title><source>Front. Vet. Sci.</source><year>2020</year><volume>7</volume><fpage>244</fpage><pub-id pub-id-type="doi">10.3389/fvets.2020.00244</pub-id><pub-id pub-id-type="pmid">32656247</pub-id></element-citation></ref><ref id="B17-pathogens-09-00889"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calixto</surname><given-names>J.B.</given-names></name><name><surname>Scheidt</surname><given-names>C.</given-names></name><name><surname>Otuki</surname><given-names>M.</given-names></name><name><surname>Santos</surname><given-names>A.R.S.</given-names></name></person-group><article-title>Biological activity of plant extracts: Novel analgesic drugs</article-title><source>Expert Opin. Emerg. Drugs</source><year>2001</year><volume>6</volume><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1517/14728214.6.2.261</pub-id><?supplied-pmid 15989526?><pub-id pub-id-type="pmid">15989526</pub-id></element-citation></ref><ref id="B18-pathogens-09-00889"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mac&#x000ea;do</surname><given-names>D.G.</given-names></name><name><surname>Ribeiro</surname><given-names>D.A.</given-names></name><name><surname>Coutinho</surname><given-names>H.D.M.</given-names></name><name><surname>Menezes</surname><given-names>I.R.A.</given-names></name><name><surname>Souza</surname><given-names>M.M.A.</given-names></name></person-group><article-title>Pr&#x000e1;ticas terap&#x000ea;uticas tradicionais: Uso e conhecimento de plantas do cerrado no estado de Pernambuco (Nordeste do Brasil)</article-title><source>Bol. Latinoam. Caribe Plantas Med. Aromat.</source><year>2015</year><volume>14</volume><fpage>491</fpage><lpage>508</lpage></element-citation></ref><ref id="B19-pathogens-09-00889"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cimanga</surname><given-names>R.K.</given-names></name><name><surname>Nsaka</surname><given-names>S.L.</given-names></name><name><surname>Tshodi</surname><given-names>M.E.</given-names></name><name><surname>Mbamu</surname><given-names>B.M.</given-names></name><name><surname>Kikweta</surname><given-names>C.M.</given-names></name><name><surname>Makila</surname><given-names>F.B.M.</given-names></name><name><surname>Cos</surname><given-names>P.</given-names></name><name><surname>Maes</surname><given-names>L.</given-names></name><name><surname>Vlietinck</surname><given-names>A.J.</given-names></name><name><surname>Exarchou</surname><given-names>V.</given-names></name><etal/></person-group><article-title>In vitro and in vivo antiplasmodial activity of extracts and isolated constituents of Alstonia congensis root bark</article-title><source>J. Ethnopharmacol.</source><year>2019</year><volume>242</volume><fpage>111736</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2019.02.019</pub-id><pub-id pub-id-type="pmid">30763695</pub-id></element-citation></ref><ref id="B20-pathogens-09-00889"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoghbi</surname><given-names>M.D.G.B.</given-names></name><name><surname>Andrade</surname><given-names>E.H.A.</given-names></name><name><surname>Carreira</surname><given-names>L.M.M.</given-names></name><name><surname>Rocha</surname><given-names>E.A.S.</given-names></name></person-group><article-title>Comparison of the main components of the essential oils of &#x0201c;priprioca&#x0201d;: <italic>Cyperus articulatus</italic> var. Articulatus, L., <italic>C. Articulatus</italic> var. <italic>Nodosus</italic>, L., <italic>C. Prolixus</italic> kunth and <italic>C. Rotundus</italic>, L.</article-title><source>J. Essent. Oil Res.</source><year>2008</year><volume>20</volume><fpage>42</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1080/10412905.2008.9699418</pub-id></element-citation></ref><ref id="B21-pathogens-09-00889"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo Bum</surname><given-names>E.</given-names></name><name><surname>Schmutz</surname><given-names>M.</given-names></name><name><surname>Meyer</surname><given-names>C.</given-names></name><name><surname>Rakotonirina</surname><given-names>A.</given-names></name><name><surname>Bopelet</surname><given-names>M.</given-names></name><name><surname>Portet</surname><given-names>C.</given-names></name><name><surname>Jeker</surname><given-names>A.</given-names></name><name><surname>Rakotonirina</surname><given-names>S.V.</given-names></name><name><surname>Olpe</surname><given-names>H.R.</given-names></name><name><surname>Herrling</surname><given-names>P.</given-names></name></person-group><article-title>Anticonvulsant properties of the methanolic extract of <italic>Cyperus articulatus</italic> (<italic>Cyperaceae</italic>)</article-title><source>J. Ethnopharmacol.</source><year>2001</year><volume>76</volume><fpage>145</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">11390127</pub-id></element-citation></ref><ref id="B22-pathogens-09-00889"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>A.</given-names></name><name><surname>Khan</surname><given-names>A.</given-names></name><name><surname>Manzoor</surname><given-names>N.</given-names></name><name><surname>Khan</surname><given-names>L.A.</given-names></name></person-group><article-title>Evolution of ergosterol biosynthesis inhibitors as fungicidal against Candida</article-title><source>Microb. Pathog.</source><year>2010</year><volume>48</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2009.10.001</pub-id><?supplied-pmid 19835945?><pub-id pub-id-type="pmid">19835945</pub-id></element-citation></ref><ref id="B23-pathogens-09-00889"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hil&#x000e1;rio</surname><given-names>F.F.</given-names></name><name><surname>de Paula</surname><given-names>R.C.</given-names></name><name><surname>Silveira</surname><given-names>M.L.T.</given-names></name><name><surname>Viana</surname><given-names>G.H.R.</given-names></name><name><surname>Alves</surname><given-names>R.B.</given-names></name><name><surname>Pereira</surname><given-names>J.R.C.S.</given-names></name><name><surname>Silva</surname><given-names>L.M.</given-names></name><name><surname>de Freitas</surname><given-names>R.P.</given-names></name><name><surname>de Pilla Varotti</surname><given-names>F.</given-names></name></person-group><article-title>Synthesis and Evaluation of Antimalarial Activity of Oxygenated 3-alkylpyridine Marine Alkaloid Analogues</article-title><source>Chem. Biol. Drug Des.</source><year>2011</year><volume>78</volume><fpage>477</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1111/j.1747-0285.2011.01154.x</pub-id><?supplied-pmid 21668650?><pub-id pub-id-type="pmid">21668650</pub-id></element-citation></ref><ref id="B24-pathogens-09-00889"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e9;nard</surname><given-names>J.</given-names></name><name><surname>Douc-Rasy</surname><given-names>S.</given-names></name><name><surname>Ahomadegbe</surname><given-names>J.C.</given-names></name></person-group><article-title>TP53 family members and human cancers</article-title><source>Hum. Mutat.</source><year>2003</year><volume>21</volume><fpage>182</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1002/humu.10172</pub-id><?supplied-pmid 12619104?><pub-id pub-id-type="pmid">12619104</pub-id></element-citation></ref><ref id="B25-pathogens-09-00889"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rukunga</surname><given-names>G.M.</given-names></name><name><surname>Muregi</surname><given-names>F.W.</given-names></name><name><surname>Omar</surname><given-names>S.A.</given-names></name><name><surname>Gathirwa</surname><given-names>J.W.</given-names></name><name><surname>Muthaura</surname><given-names>C.N.</given-names></name><name><surname>Peter</surname><given-names>M.G.</given-names></name><name><surname>Heydenreich</surname><given-names>M.</given-names></name><name><surname>Mungai</surname><given-names>G.M.</given-names></name></person-group><article-title>Anti-plasmodial activity of the extracts and two sesquiterpenes from Cyperus articulatus</article-title><source>Fitoterapia</source><year>2008</year><volume>79</volume><fpage>188</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2007.11.010</pub-id><pub-id pub-id-type="pmid">18234452</pub-id></element-citation></ref><ref id="B26-pathogens-09-00889"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Weniger</surname><given-names>H.</given-names></name></person-group><source>Review of Side Effects and Toxicity of Chloroquine</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>1979</year></element-citation></ref><ref id="B27-pathogens-09-00889"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatre</surname><given-names>C.</given-names></name><name><surname>Roubille</surname><given-names>F.</given-names></name><name><surname>Vernhet</surname><given-names>H.</given-names></name><name><surname>Jorgensen</surname><given-names>C.</given-names></name><name><surname>Pers</surname><given-names>Y.M.</given-names></name></person-group><article-title>Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature</article-title><source>Drug Saf.</source><year>2018</year><volume>41</volume><fpage>919</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1007/s40264-018-0689-4</pub-id><pub-id pub-id-type="pmid">29858838</pub-id></element-citation></ref><ref id="B28-pathogens-09-00889"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>Y.C.</given-names></name><name><surname>Hsu</surname><given-names>H.C.</given-names></name><name><surname>Yang</surname><given-names>W.C.</given-names></name><name><surname>Tsai</surname><given-names>W.J.</given-names></name><name><surname>Chen</surname><given-names>C.C.</given-names></name><name><surname>Watanabe</surname><given-names>T.</given-names></name></person-group><article-title>&#x003b1;-Bulnesene, a PAF inhibitor isolated from the essential oil of Pogostemon cablin</article-title><source>Fitoterapia</source><year>2007</year><volume>78</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2006.09.016</pub-id><pub-id pub-id-type="pmid">17107759</pub-id></element-citation></ref><ref id="B29-pathogens-09-00889"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erhirhie</surname><given-names>E.O.</given-names></name><name><surname>Ihekwereme</surname><given-names>C.P.</given-names></name><name><surname>Ilodigwe</surname><given-names>E.E.</given-names></name></person-group><article-title>Advances in acute toxicity testing: Strengths, weaknesses and regulatory acceptance</article-title><source>Interdiscip. Toxicol.</source><year>2018</year><volume>11</volume><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.2478/intox-2018-0001</pub-id><pub-id pub-id-type="pmid">30181707</pub-id></element-citation></ref><ref id="B30-pathogens-09-00889"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>E.S.S.</given-names></name><name><surname>Dolabela</surname><given-names>M.F.</given-names></name><name><surname>P&#x000f3;voa</surname><given-names>M.M.</given-names></name><name><surname>Oliveira</surname><given-names>D.J.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>A.H.</given-names></name></person-group><article-title>Estudos farmacogn&#x000f3;sticos, fitoqu&#x000ed;micos, atividade antiplasm&#x000f3;dica e toxicidade em Artemia salina de extrato etan&#x000f3;lico de folhas de <italic>Montrichardia linifera</italic> (Arruda) Schott, <italic>Araceae</italic></article-title><source>Braz. J. Pharmacogn.</source><year>2009</year><volume>19</volume><fpage>834</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1590/S0102-695X2009000600006</pub-id></element-citation></ref><ref id="B31-pathogens-09-00889"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mojarrab</surname><given-names>M.</given-names></name><name><surname>Emami</surname><given-names>S.A.</given-names></name><name><surname>Gheibi</surname><given-names>S.</given-names></name><name><surname>Taleb</surname><given-names>A.M.</given-names></name><name><surname>Heshmati Afshar</surname><given-names>F.</given-names></name></person-group><article-title>Evaluation of anti-malarial activity of Artemisia turcomanica and A. kopetdaghensis by cell-free &#x003b2;-hematin formation assay</article-title><source>Res. J. Pharmacogn.</source><year>2016</year><volume>3</volume><fpage>59</fpage><lpage>65</lpage></element-citation></ref><ref id="B32-pathogens-09-00889"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metuge</surname><given-names>J.A.</given-names></name><name><surname>Nyongbela</surname><given-names>K.D.</given-names></name><name><surname>Mbah</surname><given-names>J.A.</given-names></name><name><surname>Samje</surname><given-names>M.</given-names></name><name><surname>Fotso</surname><given-names>G.</given-names></name><name><surname>Babiaka</surname><given-names>S.B.</given-names></name><name><surname>Cho-Ngwa</surname><given-names>F.</given-names></name></person-group><article-title>Anti-Onchocerca activity and phytochemical analysis of an essential oil from <italic>Cyperus articulatus</italic> L</article-title><source>BMC Complement. Altern. Med.</source><year>2014</year><volume>14</volume><elocation-id>223</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6882-14-223</pub-id><pub-id pub-id-type="pmid">24998345</pub-id></element-citation></ref><ref id="B33-pathogens-09-00889"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>N.C.d.</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>S.F.</given-names></name><name><surname>de Ara&#x000fa;jo</surname><given-names>L.S.</given-names></name><name><surname>Kasper</surname><given-names>A.A.M.</given-names></name><name><surname>da Fonseca</surname><given-names>A.L.</given-names></name><name><surname>Sartoratto</surname><given-names>A.</given-names></name><name><surname>Castro</surname><given-names>K.C.F.</given-names></name><name><surname>Moraes</surname><given-names>T.M.P.</given-names></name><name><surname>Baratto</surname><given-names>L.C.</given-names></name><name><surname>de Varotti</surname><given-names>F.P.</given-names></name><etal/></person-group><article-title>In vitro and in vivo antimalarial activity of the volatile oil of Cyperus articulatus (<italic>Cyperaceae</italic>)</article-title><source>Acta Amaz.</source><year>2019</year><volume>49</volume><fpage>334</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1590/1809-4392201804331</pub-id></element-citation></ref><ref id="B34-pathogens-09-00889"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolabela</surname><given-names>M.F.</given-names></name><name><surname>Da Silva</surname><given-names>A.R.P.</given-names></name><name><surname>Ohashi</surname><given-names>L.H.</given-names></name><name><surname>Bastos</surname><given-names>M.L.C.</given-names></name><name><surname>Da Silva</surname><given-names>M.C.M.</given-names></name><name><surname>Vale</surname><given-names>V.V.</given-names></name></person-group><article-title>Estudo in silico das atividades de triterpenos e iridoides isolados de <italic>Himatanthus articulatus</italic> (Vahl) Woodson</article-title><source>Rev. Fitos</source><year>2018</year><volume>12</volume><fpage>227</fpage><pub-id pub-id-type="doi">10.17648/2446-4775.2018.602</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="pathogens-09-00889-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pathogens-09-00889-t001_Table 1</object-id><label>Table 1</label><caption><p>Chemical composition of the ethanolic extract of the <italic>Cyperus articulatus</italic> residue.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Identification</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">t<sub>R</sub> (min)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Rel%</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">alpha-bulnesene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.18</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cadalene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.36</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cyperotundone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.88</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cis-thujopsenal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cyclocolorenone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.75</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">corymbolone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.25</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hexadecanoic acid ethyl ester</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.99</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9,12-octadecadienic acid ethyl ester</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.24</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9-octadecenoic acid ethyl ester</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cholesta-3,5-diene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.82</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total identified:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.16</td></tr></tbody></table><table-wrap-foot><fn><p>t<sub>R</sub>: retention time; Rel%: relative percentage.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pathogens-09-00889-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pathogens-09-00889-t002_Table 2</object-id><label>Table 2</label><caption><p>In vitro antiplasmodial activity, cytotoxicity (human lung fibroblast, Wi 26VA-4), and selectivity index (SI) of ethanolic extract of <italic>Cyperus articulatus</italic> rhizomes against <italic>Plasmodium falciparum</italic> strains W2 and 3D7, and using chloroquine as control.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">IC<sub>50</sub> (&#x000b5;g/mL) &#x000b1; SD *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antiplasmodial Activity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LC<sub>50</sub> (&#x000b5;g)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">SI</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3D7</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">W2</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3D7</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">W2</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ethanolic Extract</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.10 &#x000b1; 0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.21 &#x000b1; 0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e; 100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e; 91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chloroquine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.46 &#x000b1; 0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.21 &#x000b1; 0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e; 100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e; 200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e; 200</td></tr></tbody></table><table-wrap-foot><fn><p>IC<sub>50</sub>: average inhibitory concentration; LC<sub>50</sub>: mean lethal concentration. * Values are expressed by mean &#x000b1; SD (standard deviation).</p></fn></table-wrap-foot></table-wrap></floats-group></article>